Adarx Pharmaceuticals
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Adarx Pharmaceuticals (ADRX) | 1.42B | -13.98 | 2.48 | 0.00% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 19.4% below Morningstar's fair value estimate.
Fair value
Adarx Pharmaceuticals Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $15.28 per share; however, caution is warranted due to this estimate's very high uncertainty rating.
The company's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 3.3 falls in the bottom 40% compared with peers globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.
On a different note, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, lies in the top 40% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none.
By Quantitative Equity Report
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
Adarx Pharmaceuticals discussion 0 comments